Congenital, Heart Transplant and Sickle Cell Disease

Lantheus Announces the FDA Approval of DEFINITY as Ultrasound Enhancing Agent for Use in Certain Pediatric Cardiovascular Patients

DAIC

MARCH 6, 2024

Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly. 5 Kutty, S.,

Pediatrics

Pediatrics Ultrasound Heart Transplant Echocardiogram

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Cardiovascular Update

Lantheus Announces the FDA Approval of DEFINITY as Ultrasound Enhancing Agent for Use in Certain Pediatric Cardiovascular Patients

Published Research

Published Research

Stay Connected